These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 11323196)

  • 1. Cholesterol biosynthesis regulation and protein changes in rat liver following treatment with fluvastatin.
    Steiner S; Gatlin CL; Lennon JJ; McGrath AM; Seonarain MD; Makusky AJ; Aponte AM; Esquer-Blasco R; Anderson NL
    Toxicol Lett; 2001 Mar; 120(1-3):369-77. PubMed ID: 11323196
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proteomics to display lovastatin-induced protein and pathway regulation in rat liver.
    Steiner S; Gatlin CL; Lennon JJ; McGrath AM; Aponte AM; Makusky AJ; Rohrs MC; Anderson NL
    Electrophoresis; 2000 Jun; 21(11):2129-37. PubMed ID: 10892724
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The safety evaluation of fluvastatin, an HMG-CoA reductase inhibitor, in beagle dogs and rhesus monkeys.
    Hartman HA; Myers LA; Evans M; Robison RL; Engstrom RG; Tse FL
    Fundam Appl Toxicol; 1996 Jan; 29(1):48-62. PubMed ID: 8838639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
    Lennernäs H; Fager G
    Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HMG-CoA reductase inhibitors induce apoptosis of lymphoma cells by promoting ROS generation and regulating Akt, Erk and p38 signals via suppression of mevalonate pathway.
    Qi XF; Zheng L; Lee KJ; Kim DH; Kim CS; Cai DQ; Wu Z; Qin JW; Yu YH; Kim SK
    Cell Death Dis; 2013 Feb; 4(2):e518. PubMed ID: 23449454
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective inhibition of cholesterol synthesis in liver versus extrahepatic tissues by HMG-CoA reductase inhibitors.
    Parker RA; Clark RW; Sit SY; Lanier TL; Grosso RA; Wright JJ
    J Lipid Res; 1990 Jul; 31(7):1271-82. PubMed ID: 2401858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sterol regulatory element binding protein-mediated effect of fluvastatin on cytosolic 3-hydroxy-3-methylglutaryl-coenzyme A synthase transcription.
    Mascaró C; Ortiz JA; Ramos MM; Haro D; Hegardt FG
    Arch Biochem Biophys; 2000 Feb; 374(2):286-92. PubMed ID: 10666309
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of cholesterol synthesis ex vivo and in vivo by fluvastatin, a new inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase.
    Yamamoto A; Itoh S; Hoshi K; Ichihara K
    Experientia; 1995 Mar; 51(3):223-6. PubMed ID: 7698284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Species differences in the inhibiting effect of fluvastatin, a new inhibitor of HMG-CoA reductase, on cholesterol biosynthesis.
    Yamamoto A; Itoh S; Hoshi K; Ichihara K
    Res Commun Mol Pathol Pharmacol; 1994 Dec; 86(3):325-34. PubMed ID: 7712108
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High dose of fluvastatin sodium (XU62-320), a new inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, lowers plasma cholesterol levels in homozygous Watanabe-heritable hyperlipidemic rabbits.
    Kurokawa J; Hayashi K; Toyota Y; Shingu T; Shiomi M; Kajiyama G
    Biochim Biophys Acta; 1995 Oct; 1259(1):99-104. PubMed ID: 7492622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Fluvastatin in the treatment of hyperlipoproteinemia, initial experience].
    Ceska R
    Vnitr Lek; 1996 Aug; 42(8):533-6. PubMed ID: 8967021
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A review of current clinical findings with fluvastatin.
    Garnett WR
    Am J Cardiol; 1996 Sep; 78(6A):20-5. PubMed ID: 8875971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of fluvastatin sodium (XU62-320), a new inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on the induction of low-density lipoprotein receptor in HepG2 cells.
    Hayashi K; Kurokawa J; Nomura S; Kuga Y; Ohkura Y; Kajiyama G
    Biochim Biophys Acta; 1993 Apr; 1167(2):223-5. PubMed ID: 8466953
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of alcohol and fluvastatin on lipid metabolism and hepatic function.
    Smit JW; Wijnne HJ; Schobben F; Sitsen A; De Bruin TW; Erkelens DW
    Ann Intern Med; 1995 May; 122(9):678-80. PubMed ID: 7702230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The phototoxicity of fluvastatin, an HMG-CoA reductase inhibitor, is mediated by the formation of a benzocarbazole-like photoproduct.
    Viola G; Grobelny P; Linardi MA; Salvador A; Basso G; Mielcarek J; Dall'Acqua S; Vedaldi D; Dall'Acqua F
    Toxicol Sci; 2010 Nov; 118(1):236-50. PubMed ID: 20668001
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fluvastatin: a review of its pharmacology and use in the management of hypercholesterolaemia.
    Plosker GL; Wagstaff AJ
    Drugs; 1996 Mar; 51(3):433-59. PubMed ID: 8882381
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical pharmacokinetics of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors.
    Desager JP; Horsmans Y
    Clin Pharmacokinet; 1996 Nov; 31(5):348-71. PubMed ID: 9118584
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HMG-CoA reductase inhibitor fluvastatin prevents angiotensin II-induced cardiac hypertrophy via Rho kinase and inhibition of cyclin D1.
    Morikawa-Futamatsu K; Adachi S; Maejima Y; Tamamori-Adachi M; Suzuki J; Kitajima S; Ito H; Isobe M
    Life Sci; 2006 Aug; 79(14):1380-90. PubMed ID: 16712874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibitory effects of fluvastatin, a new HMG-CoA reductase inhibitor, on the increase in vascular ACE activity in cholesterol-fed rabbits.
    Mitani H; Bandoh T; Ishikawa J; Kimura M; Totsuka T; Hayashi S
    Br J Pharmacol; 1996 Nov; 119(6):1269-75. PubMed ID: 8937733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Possible mechanisms underlying statin-induced skeletal muscle toxicity in L6 fibroblasts and in rats.
    Itagaki M; Takaguri A; Kano S; Kaneta S; Ichihara K; Satoh K
    J Pharmacol Sci; 2009 Jan; 109(1):94-101. PubMed ID: 19129682
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.